Core A - Clinical Database.
Core A - Clinical Database.
批准号:
10311213
负责人:
PETER WESTERVELT
金额:
$33.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-19 至 2023-11-30
关键词:
Acute Myelocytic LeukemiaBiological Specimen databaseBone MarrowCancer CenterCharacteristicsClinicalClinical DataClinical ResearchClonal EvolutionDNA SequenceDNA sequencingDataData AnalysesData SetDatabase Management SystemsDatabasesDiagnosisDiseaseDisease remissionEnrollmentEnsureEvaluationGene ExpressionGenomicsGoalsHumanInformaticsLeukocytesLinkMalignant NeoplasmsManuscriptsMolecularMusMutationNormal tissue morphologyOral mucous membrane structureOutcomePathologicPatientsPreparationProceduresProcessPrognostic FactorProtocols documentationPublicationsRelapseResidual NeoplasmSample SizeSamplingSerumServicesSkinSpecimenSwabTherapeuticTimeTissue BanksTissuesTumor TissueUniversitiesWashingtonclinical databaseepidemiologic dataleukemianext generationperipheral bloodprogramsprospectivequality assurancesuccesstherapy outcome
中文摘要
核心A摘要/摘要
该核心研究的主要目标是招募转诊至华盛顿大学的每位AML和MDS患者
GAML程序项目的组织采集和临床数据库方案。皮肤、口腔粘膜、骨
将从患者中采集的骨髓、外周血白细胞和血清样本进行储存和处理
核心B(样本数据库),因此它们将作为核心中概述的基因组分析的基础
C(测序和分析),将用于项目1-4。该临床核心还将维持和扩大
全面的数据库,涵盖基本的临床,病理,核型,分子,治疗,
入组AML和MDS患者的结局数据,与相应的组织标本匿名关联。
临床核心数据库将为核心B制备的样本提供关键临床注释,
由核心C进行的研究,将由项目1-4使用。
具体目标/核心服务1:
我们将尝试前瞻性地招募和收集诊断时、缓解时和复发时的组织,
患者因AML和MDS转诊至华盛顿大学Siteman癌症中心。
具体目标/核心服务2:
我们将维持一个全面的临床白血病数据库,收集流行病学数据,疾病-
所有入组AML的相关特征、预后因素、治疗信息和结局数据,
MDS患者,与相应的库存组织标本存在去识别关联。
具体目标/核心服务3:
我们将为所有PPG活动提供统计和信息支持,包括样本量评估,
人类和小鼠研究,所有出版物数据集的详细统计评价,以及
数据库管理
英文摘要
CORE A SUMMARY/ABSTRACT
The main objective of this core is the enrollment of every patient AML and MDS referred to Washington University
into the Tissue Acquisition and Clinical Database protocol of the GAML program project. Skin, oral mucosa, bone
marrow, peripheral blood leukocytes and serum specimens collected from patients will be banked and processed
by Core B, (Specimen Database), whereupon they will serve as the basis for genomic analyses outlined in Core
C (Sequencing and Analysis), to be utilized in Projects 1-4. This Clinical Core will also maintain and expand a
comprehensive database that captures essential clinical, pathological, karyotypic, molecular, therapeutic, and
outcomes data of enrolled AML and MDS patients, anonymously linked with the corresponding tissue specimens.
The Clinical Core database will provide key clinical annotation for the samples prepared by Core B, and genomic
studies performed by Core C, which will be utilized by Projects 1-4.
Specific Aim/Core Service 1:
We will attempt to prospectively enroll and collect tissue at diagnosis, in remission, and at relapse from every
patient referred to the Washington University Siteman Cancer Center with AML and MDS.
Specific Aim/Core Service 2:
We will maintain a comprehensive clinical leukemia database that will capture epidemiological data, disease-
related characteristics, prognostic factors, therapeutic information, and outcomes data from all enrolled AML and
MDS patients, with de-identified linkage to corresponding banked tissue specimens.
Specific Aim/Core Service 3:
We will provide statistical and informatics support for all PPG activities, including sample size assessments for
human and mouse studies, detailed statistical evaluations of all datasets for publications, and IT support for
database management.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:10430084
-
项目类别:
-
资助金额:$16.57万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:9385676
-
项目类别:
-
资助金额:$14.89万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:10165782
-
项目类别:
-
资助金额:$16.96万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:9535449
-
项目类别:
-
资助金额:$17.05万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Biospecimen Processing.
-
批准号:10439619
-
项目类别:
-
资助金额:$18.63万
-
财政年份:2013
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Biospecimen Processing.
-
批准号:10931074
-
项目类别:
-
资助金额:$11.83万
-
财政年份:2013
-
负责人:PETER WESTERVELT
-
依托单位:
Biospecimen Processing
-
批准号:8595804
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2013
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Biospecimen Processing.
-
批准号:10194396
-
项目类别:
-
资助金额:$13.95万
-
财政年份:2013
-
负责人:PETER WESTERVELT
-
依托单位:
Clinical Database
-
批准号:8375669
-
项目类别:
-
资助金额:$15.38万
-
财政年份:2012
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8316237
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8495404
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8678988
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:9069955
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8174305
-
项目类别:
-
资助金额:$15.05万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Clinical Database
-
批准号:7465880
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2008
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Clinical Database.
-
批准号:10541179
-
项目类别:
-
资助金额:$35.03万
-
财政年份:2003
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:6474959
-
项目类别:
-
资助金额:$9.94万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:2823311
-
项目类别:
-
资助金额:$11.2万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:6536544
-
项目类别:
-
资助金额:$13.43万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:6388519
-
项目类别:
-
资助金额:$1.78万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位: